Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 10/20 | 0.37 |
| ▸ | PRSS8 | Q16651 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870014 | 0.89 | FAAH (0.40) | CMA1FAAHCES1DAGLAXDH | |
| SCHEMBL5800404 | 0.85 | CTSS (0.43) | FAAHCES1DAGLACTSSCYP3A4 | |
| SCHEMBL5774425 | 0.76 | DAGLA (0.43) | FAAHCES1DAGLAXDHKDM4E | |
| SCHEMBL3873339 | 0.76 | CTSS (0.40) | CMA1FAAHCES1DAGLAXDH | |
| SCHEMBL3877756 | 0.75 | CTSS (0.47) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL3873491 | 0.75 | XDH (0.39) | FAAHCES1DAGLAXDHKDM4E | |
| SCHEMBL3870461 | 0.72 | MMP1 (0.40) | FAAHCES1RAB9A | |
| SCHEMBL3869386 | 0.72 | CTSS (0.35) | CTSSRAB9A | |
| SCHEMBL3872602 | 0.71 | LIPG (0.32) | CTSSKDM4ERAB9ACYP2C9 | |
| SCHEMBL3870369 | 0.70 | CTSS (0.43) | CMA1FAAHCES1DAGLACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CMA1 19/4885FAAH 1034/4885CES1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.